Results 11 to 20 of about 49,135 (301)

Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants. [PDF]

Br J Clin Pharmacol
Aims To evaluate the effects of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) oestrogen receptor degrader, on the pharmacokinetics of dabigatran (a P‐glycoprotein [P‐gp] substrate) and rosuvastatin (a breast cancer resistance protein [BCRP] substrate).
Yang DZ, Zhou L, Winton JA, Matschke KT, Kantaridis C, Doyle K, Lee KC, Chen N, Zhang Y, Tan W.   +9 more
europepmc   +2 more sources

Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding

Perspectives in Clinical Research, 2023
Background: Dabigatran is the first oral direct thrombin inhibitor which is endorsed by Food and Drug Administration in the prevention of embolic events in patients with nonvalvular atrial fibrillation.
Anitta Shaji, Doody Thomas, Midhuna Saju, Suja Abraham, Ramdas Nayak   +4 more
doaj   +1 more source

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]

, 2012
Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Bohmann, Ferdinand, Förch, Christian, Lindhoff-Last, Edelgard, Mirceska, Ana, Pfeilschifter, Josef Martin (Prof. Dr.), Pfeilschifter, Waltraud, Steinmetz, Helmuth   +6 more
core   +15 more sources

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran [PDF]

Pharmaceutics, 2022
Dabigatran (DAB) is an orally administered thrombin inhibitor. Both DAB and its main metabolite dabigatran acylglucuronide (DABG) have established anticoagulant effects. Here, we aimed to compare the relative anticoagulant effects of DABG and DAB in humans.
Jong-Min Kim, Jihyeon Noh, Jin-Woo Park, Hyewon Chung, Kyoung-Ah Kim, Seung Bin Park, Jun-Seok Lee, Ji-Young Park   +7 more
openaire   +3 more sources

Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study

International Journal of Stroke, 2023
Background: The optimal timing of initiating or resuming anticoagulation after acute ischemic stroke (AIS) or transient ischemic attack (TIA) in patients with atrial fibrillation (AF) is debated. Dabigatran, a non-vitamin K oral anticoagulant (NOAC), has
G. Grosse, Anika Hüsing, A. Stang, N. Kuklik, M. Brinkmann, D. Nabavi, P. Sparenberg, K. Weissenborn, K. Gröschel, G. Royl, Sven Poli, D. Michalski, C. Eschenfelder, C. Weimar, Hans-Christoph Diener   +14 more
semanticscholar   +1 more source

The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports [PDF]

Arhiv za farmaciju, 2020
Dabigatran is a novel oral anticoagulant preferred due to its ease of use, favorable pharmacokinetics, decreased potential for drug-drug interactions, and the lack of monitoring requirements.
Tomić Milan
doaj   +1 more source

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry

Clinical Research in Cardiology, 2022
Prospectively collected, routine clinical practice-based data on antithrombotic therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world comparative outcomes.
M. Huisman, C. Teutsch, Shihai Lu, Hans-Christoph Diener, S. Dubner, J. Halperin, Chang-Sheng Ma, K. Rothman, Ragna Lohmann, V. K. Gurusamy, D. Bartels, G. Lip   +11 more
semanticscholar   +1 more source

Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial

BMC Medicine, 2022
Observational studies support a role for oral anticoagulation to reduce the risk of dementia in atrial fibrillation patients, but conclusive data are lacking.
B. Caramelli, P. C. Yu, F. A. Cardozo, I. Magalhães, R. Spera, D. K. Amado, M. C. Escalante-Rojas, D. Gualandro, D. Calderaro, C. Tavares, Flávio A. Borges-Júnior, A. Pastana, M. Matheus, S. Brucki, A. C. Rodrigues, R. Nitrini, P. Caramelli   +16 more
semanticscholar   +1 more source

Dabigatran (Pradaxa) [PDF]

American Journal of Neuroradiology, 2012
Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less ...
J, Comin, D F, Kallmes
openaire   +2 more sources

Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia

Life, 2022
Background and Purpose: Thrombophilic gene alterations are a major risk factor for cerebral sinus vein thrombosis (CSVT). Up to 30% of all patients with cerebral sinus vein thrombosis (CSVT) are found to have thrombophilic defects such as prothrombin ...
Lukas Kellermair, Matthias W. G. Zeller, Caterina Kulyk, Josef Tomasits, Tim J. von Oertzen, Milan R. Vosko   +5 more
doaj   +1 more source